^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PD-L1 expression

    i
    Entrez ID:
    29126
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    Related tests:
    Apply
    Study of Longitudinal Plasma PD-L1 Testing With Immunotherapy in Lung Cancer (NCT06849518)
    Phase N/A
    Ballad Health
    Recruiting
    Last update posted :
    02/28/2025
    Initiation :
    02/11/2025
    Primary completion :
    03/01/2026
    Completion :
    03/01/2027
    PD-L1
    |
    PD-L1 expression
    Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer (NCT05642195)
    Phase 1/2
    National Cancer Institute (NCI)
    Suspended
    Last update posted :
    02/24/2025
    Initiation :
    02/27/2025
    Primary completion :
    12/30/2033
    Completion :
    12/30/2035
    PD-L1
    |
    PD-L1 expression
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • H1299 lung cancer cell lysate vaccine with Montanide ISA-51 VG adjuvant
    Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study (NCT02997228)
    Phase 3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    01/19/2018
    Primary completion :
    06/01/2027
    Completion :
    06/01/2027
    PD-L1 • MSI • MLH1 • MSH6 • MSH2
    |
    PD-L1 expression • BRAF V600E • MSI-H/dMMR
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • 5-fluorouracil • oxaliplatin • Aybintio (bevacizumab biosimilar) • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Krabeva (bevacizumab biosimilar) • fluorouracil topical • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)
    Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy (NCT04963153)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    07/07/2022
    Primary completion :
    09/01/2025
    Completion :
    09/01/2025
    PD-L1 • FGFR2 • NECTIN4
    |
    PD-L1 expression
    |
    Balversa (erdafitinib) • Padcev (enfortumab vedotin-ejfv)
    Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial (ACCIO) (NCT04267848)
    Phase 3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    06/16/2020
    Primary completion :
    12/15/2025
    Completion :
    12/15/2025
    EGFR • PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • pemetrexed • Pembroria (pembrolizumab biosimilar) • liposomal gemcitabine (FF-10832)
    Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery (SWOG 1512) (NCT02775851)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    02/06/2017
    Primary completion :
    04/14/2023
    Completion :
    05/15/2026
    TMB • CD8 • CD4
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)
    A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC (AdvanTIG-206) (NCT04948697)
    Phase 2
    BeiGene
    Completed
    Last update posted :
    02/24/2025
    Initiation :
    08/20/2021
    Primary completion :
    02/01/2024
    Completion :
    02/01/2024
    PD-L1
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab-jsgr) • Avzivi (bevacizumab-tnjn) • ociperlimab (BGB-A1217)
    SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma (NCT03138161)
    Phase 1/2
    Sarcoma Oncology Research Center, LLC
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    04/13/2017
    Primary completion :
    12/31/2030
    Completion :
    07/31/2031
    PD-L1 • PD-1
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Yondelis (trabectedin)
    Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers (ECOG-ACRIN EA3202) (NCT05063552)
    Phase 2/3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    03/13/2023
    Primary completion :
    12/15/2027
    Completion :
    12/15/2027
    PD-L1
    |
    PD-L1 expression
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • cisplatin • Tecentriq (atezolizumab) • carboplatin • docetaxel • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer (NCT04243616)
    Phase 2
    Medical College of Wisconsin
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    03/05/2020
    Primary completion :
    07/14/2025
    Completion :
    08/13/2025
    HER-2 • PD-L1 • PGR • PD-L2
    |
    PD-L1 expression • HER-2 negative • PGR positive
    |
    carboplatin • albumin-bound paclitaxel • cyclophosphamide • pegylated liposomal doxorubicin • Libtayo (cemiplimab-rwlc) • cyclophosphamide intravenous • doxorubicin liposomal
    Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia (NCT04712851)
    Phase 2
    Jonsson Comprehensive Cancer Center
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    06/30/2021
    Primary completion :
    01/31/2026
    Completion :
    01/31/2027
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab)
    A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer (NAUTIKA1) (NCT04302025)
    Phase 2
    Genentech, Inc.
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    11/06/2020
    Primary completion :
    12/30/2025
    Completion :
    03/06/2029
    PD-L1 • KRAS • BRAF • ALK • RET • ROS1 • NTRK1 • NTRK3 • NTRK2
    |
    PD-L1 expression • KRAS mutation • KRAS G12C • BRAF mutation • BRAF V600 • RET fusion • ALK fusion • RET mutation • ROS1 fusion • KRAS G12
    |
    Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • Rozlytrek (entrectinib) • Alecensa (alectinib) • Cotellic (cobimetinib) • Gavreto (pralsetinib) • divarasib (RG6330)
    Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma with High-risk Recurrence Factors (NCT04669496)
    Phase 2/3
    Shanghai Zhongshan Hospital
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    01/20/2021
    Primary completion :
    12/01/2025
    Completion :
    12/01/2026
    TMB • MSI • CEACAM5 • MUC16
    |
    PD-L1 expression
    |
    Lenvima (lenvatinib) • Loqtorzi (toripalimab-tpzi) • oxaliplatin
    A Study of SGN-PDL1V in Advanced Solid Tumors (SGNPDL1V-001) (NCT05208762)
    Phase 1
    Seagen Inc.
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    10/25/2022
    Primary completion :
    11/18/2027
    Completion :
    11/17/2028
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • PF-08046054
    Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies (20-C-0012) (NCT04235777)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    07/13/2020
    Primary completion :
    12/01/2027
    Completion :
    12/01/2027
    CD4
    |
    PD-L1 expression
    |
    bintrafusp alfa (M7824) • PDS01ADC
    Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients (HARMONi-3) (NCT05899608)
    Phase 3
    Summit Therapeutics
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    10/26/2023
    Primary completion :
    12/31/2027
    Completion :
    12/31/2028
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Yidafan (ivonescimab)
    Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists (CHECK'UP) (NCT03412058)
    Phase N/A
    UNICANCER
    Active, not recruiting
    Last update posted :
    02/20/2025
    Initiation :
    06/27/2018
    Primary completion :
    01/02/2024
    Completion :
    12/01/2025
    EGFR • ALK
    |
    PD-L1 expression • PD-L1 overexpression • ALK negative
    A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) (NCT05920356)
    Phase 3
    Amgen
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    11/16/2023
    Primary completion :
    06/30/2026
    Completion :
    06/30/2031
    PD-L1 • KRAS
    |
    PD-L1 expression • PD-L1 negative
    |
    Keytruda (pembrolizumab) • carboplatin • Lumakras (sotorasib)
    A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants with Advanced Solid Tumors (NCT05821777)
    Phase 1/2
    Centessa Pharmaceuticals (UK) Limited
    Active, not recruiting
    Last update posted :
    02/20/2025
    Initiation :
    03/28/2023
    Primary completion :
    10/01/2025
    Completion :
    01/05/2027
    PD-L1 • MSI
    |
    PD-L1 expression
    |
    itanistomig (LB101)
    A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (Morpheus Lung) (NCT03337698)
    Phase 1/2
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    02/20/2025
    Initiation :
    12/27/2017
    Primary completion :
    09/30/2025
    Completion :
    11/30/2026
    PD-L1
    |
    PD-L1 expression
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • gemcitabine • docetaxel • Cotellic (cobimetinib) • pemetrexed • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • Repatha (evolocumab) • camonsertib (RP-3500) • cibisatamab (RG7802) • ciforadenant (CPI-444) • zanzalintinib (XL092)
    A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors (NCT05487235)
    Phase 1
    Genentech, Inc.
    Active, not recruiting
    Last update posted :
    02/20/2025
    Initiation :
    08/17/2022
    Primary completion :
    03/31/2026
    Completion :
    03/31/2026
    EGFR • BRAF • ALK
    |
    PD-L1 expression • BRAF wild-type
    |
    Tecentriq (atezolizumab) • migoprotafib (RLY-1971) • omeprazole
    A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (NCT05852691)
    Phase 2
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    02/19/2025
    Initiation :
    07/18/2023
    Primary completion :
    12/24/2026
    Completion :
    12/24/2026
    HER-2 • PD-L1 • ER • CD4
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • albumin-bound paclitaxel • tobemstomig (RG6139)
    Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC (JS001-027-III-HCC) (NCT04523493)
    Phase 3
    Shanghai Junshi Bioscience Co., Ltd.
    Active, not recruiting
    Last update posted :
    02/19/2025
    Initiation :
    06/29/2020
    Primary completion :
    05/31/2025
    Completion :
    09/01/2026
    PD-L1 • TMB
    |
    PD-L1 expression
    |
    Lenvima (lenvatinib) • Loqtorzi (toripalimab-tpzi)
    Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative (NCT04929041)
    Phase 2/3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    10/07/2022
    Primary completion :
    12/31/2027
    Completion :
    12/31/2027
    EGFR • PD-L1 • ALK • ROS1
    |
    PD-L1 expression • ALK mutation
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • paclitaxel • albumin-bound paclitaxel • pemetrexed • ABP 206 (nivolumab biosimilar) • Pembroria (pembrolizumab biosimilar) • Pemfexy (pemetrexed)
    Study of CTDNA Response Adaptive Immuno-Chemotherapy in NSCLC (NCT04093167)
    Phase 2/3
    Canadian Cancer Trials Group
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    05/26/2020
    Primary completion :
    12/31/2026
    Completion :
    07/30/2027
    EGFR • PD-L1 • ALK
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab)
    Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & Taxanes (KELLY) (NCT03222856)
    Phase 2
    MedSIR
    Completed
    Last update posted :
    02/19/2025
    Initiation :
    12/14/2017
    Primary completion :
    10/31/2018
    Completion :
    12/23/2020
    HER-2 • PD-L1 • ER • PGR • TMB
    |
    PD-L1 expression • HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    Keytruda (pembrolizumab) • Halaven (eribulin mesylate)
    Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy (NCT06439836)
    Phase 1
    National Cancer Institute (NCI)
    Not yet recruiting
    Last update posted :
    02/18/2025
    Initiation :
    02/21/2025
    Primary completion :
    06/01/2027
    Completion :
    06/01/2027
    PD-L1 • CD68 • CRP
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • emavusertib (CA-4948)
    Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies (NCT04181788)
    Phase 2
    Pfizer
    Active, not recruiting
    Last update posted :
    02/18/2025
    Initiation :
    03/18/2020
    Primary completion :
    03/03/2022
    Completion :
    04/30/2025
    EGFR • PD-L1 • BRAF • ALK • ROS1
    |
    PD-L1 expression • EGFR mutation • BRAF mutation • ALK translocation
    |
    sasanlimab (PF-06801591)
    A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors (ST316-101) (NCT05848739)
    Phase 1
    Sapience Therapeutics
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    06/05/2023
    Primary completion :
    05/31/2026
    Completion :
    05/31/2027
    PD-L1 • MSI • BRCA
    |
    PD-L1 expression • MSI-H/dMMR • BRCA mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • irinotecan • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil) • leucovorin calcium • ST316
    Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours (NCT02879162)
    Phase 2
    Canadian Cancer Trials Group
    Completed
    Last update posted :
    02/17/2025
    Initiation :
    12/14/2016
    Primary completion :
    06/20/2021
    Completion :
    01/29/2025
    PD-L1
    |
    PD-L1 expression
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Patient-derived Organoids and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC) (NCT06405230)
    Phase 1/2
    GlaxoSmithKline
    Not yet recruiting
    Last update posted :
    02/17/2025
    Initiation :
    02/28/2025
    Primary completion :
    12/16/2027
    Completion :
    06/01/2028
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • Jemperli (dostarlimab-gxly)
    Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET) (NCT05700721)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    06/02/2023
    Primary completion :
    08/07/2025
    Completion :
    08/07/2027
    PD-L1 • HRD • CDK12 • CHEK2 • RAD51 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • RAD54L • FANCL • RAD52
    |
    PD-L1 expression
    |
    Zejula (niraparib) • Jemperli (dostarlimab-gxly)
    Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma (NCT05303493)
    Phase 1
    Centre hospitalier de l'Université de Montréal ...
    Recruiting
    Last update posted :
    02/14/2025
    Initiation :
    06/29/2022
    Primary completion :
    04/15/2025
    Completion :
    04/15/2027
    PD-L1 • BRAF
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab)
    Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors (BGB-900-102) (NCT03744468)
    Phase 1/2
    BeiGene
    Completed
    Last update posted :
    02/14/2025
    Initiation :
    11/13/2018
    Primary completion :
    02/06/2025
    Completion :
    02/06/2025
    PD-L1
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab-jsgr) • alcestobart (LBL-007) • surzebiclimab (BGB-A425)
    Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma (RATIONALE 305) (NCT03777657)
    Phase 3
    BeiGene
    Completed
    Last update posted :
    02/14/2025
    Initiation :
    12/13/2018
    Primary completion :
    02/28/2023
    Completion :
    08/27/2024
    PD-L1
    |
    PD-L1 expression
    |
    cisplatin • 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin
    Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007) (NCT03829332)
    Phase 3
    Merck Sharp & Dohme LLC
    Completed
    Last update posted :
    02/14/2025
    Initiation :
    03/13/2019
    Primary completion :
    05/19/2021
    Completion :
    04/24/2024
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors (NCT02496208)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/13/2025
    Initiation :
    07/22/2015
    Primary completion :
    09/30/2026
    Completion :
    09/30/2026
    PD-L1
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)
    Denosumab and Nivolumab Combination As 2d-line Therapy in Stage IV NSC Lung Cancer with Bone Metastases (DENIVOS) (NCT03669523)
    Phase 2
    Centre Hospitalier Annecy Genevois
    Completed
    Last update posted :
    02/13/2025
    Initiation :
    11/06/2018
    Primary completion :
    10/19/2023
    Completion :
    10/19/2023
    EGFR • PD-L1 • BRAF • ALK
    |
    PD-L1 expression • EGFR mutation • BRAF mutation • BRAF V600 • ALK translocation
    |
    Opdivo (nivolumab) • Prolia (denosumab) • zoledronic acid
    Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (NeoCOAST-2) (NCT05061550)
    Phase 2
    AstraZeneca
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    04/14/2022
    Primary completion :
    05/09/2030
    Completion :
    05/09/2030
    EGFR • PD-L1 • ALK
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • Datroway (datopotamab deruxtecan) • oleclumab (MEDI9447) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • falbikitug (AZD0171) • monalizumab (IPH2201)
    A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC (ARTEMIDE-01) (NCT04995523)
    Phase 1/2
    AstraZeneca
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    09/14/2021
    Primary completion :
    08/18/2026
    Completion :
    03/16/2028
    PD-L1
    |
    PD-L1 expression
    |
    rilvegostomig (AZD2936)